New Nasal Spray Claims to Reduce CCP Virus Infectivity by Over 99 Percent in 30 Seconds: Scripps Research Institute

A battle is on in the courts over whether certain nasal sprays can be used as a treatment, or preventative, for COVID 19. (Thorsten Frenzel/Pixabay)

The developer of a nasal spray is claiming that its anti-viral nasal spray may significantly reduce the infectivity of respiratory and cold viruses, including the CCP (Chinese Communist Party) virus.

The data published on July 27, by the Australian-based company Starpharma claims that its research at the Scripps Research Institute in the United States into astodrimer sodium (SPL7013) revealed the substance was able to inactivate over 99 percent of the CCP virus, including the Delta and Kappa variants.

“We are very pleased to confirm the rapid virucidal activity of SPL7013, with greater than 99.99 percent reduction of infectious virus in just 30 seconds against the Delta variant,” Starpharma CEO Jackie Fairley said. “The Delta variant continues to challenge public health responses worldwide—most recently triggering lockdowns and emergency restrictions in Australia, Japan, and Indonesia.”

The company also says its Viraleze nasal spray works against other viruses such as RSV, SARS, and MERS.

Professor Philippe Gallay from the Scripps Research Institute said it was remarkable that astodrimer sodium demonstrated potency against the various strains of COVID-19.

“SPL7013 acts as a barrier to viral infection, and its broad-spectrum activity demonstrates its resilience against a rapidly changing target,” Gallay said.

A spokesman for Federal Health Minister Greg Hunt told The Epoch Times that the currently available data for the spray, which shows that it is virucidal, is pre-clinical data.

“There is currently no clinical data available to show the safety or efficacy of VIRALEZE,” the spokesman said. “However, a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetic study of VIRALEZE nasal spray is currently underway.”

“Any recommendation regarding the use of this product would depend on an analysis of evidence from clinical trials regarding its safety and efficacy.”

Viraleze is not yet approved by Australia’s Therapeutic Goods Administration (TGA) but is available in Europe and India. The TGA fined Starpharma $93,240 (US$68,863) this month for advertising its product to Australian consumers while it was still unapproved.

Independent MP Craig Kelly said he wasn’t familiar with the new substance, but that everyone should look at the science, the research, and the evidence around medicines that treat COVID-19.

“We hear that premiers and prime ministers regularly say, ‘we take advice from medical experts.’” Kelly told The Epoch Times. “Well, I think it’s time they got a second opinion because there are many other medical experts that have a completely different opinion to what the official state line is.”

Kelly has been de-platformed by Facebook and Instagram for sharing information about alternative therapies for the novel coronavirus.